The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
about
Phenotype standardization for statin-induced myotoxicityMuscular effects of statins in the elderly female: a reviewPediatric Statin Administration: Navigating a Frontier with Limited DataAdherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register studyInvestigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic studyPhysiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.Impact of OATP transporters on pharmacokinetics.The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARĪ± and its relevance to hepatotoxicity.Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.Cytochrome P450 Enzyme Metabolites in Lead Discovery and Development.A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy.Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.Fluvastatin and fluvastatin extended release: a clinical and safety profile.Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutionsMechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI)Transporters and their impact on drug disposition.Rosuvastatin for the treatment of hypercholesterolemia.Retracted: Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans.Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.Combinatorial pharmacogenetics.Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates.Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.Drug-drug interaction pattern recognition.Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease.Drug-drug interaction studies: regulatory guidance and an industry perspectiveTransporter-mediated uptake into cellular compartments.Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.Role of OATP transporters in the disposition of drugs.Myotoxicity of gemfibrozil in cynomolgus monkey model and its relationship to pharmacokinetic properties.Efficacy and safety of rosuvastatin in the management of dyslipidemiaEffects of drug transporters on volume of distribution.Fenofibrate: treatment of hyperlipidemia and beyond.Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytesHepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver.Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
P2860
Q27020935-342E1ECA-ABF0-4EAC-81F6-B50B42A92190Q27023343-308F75A3-61AE-4A37-BAF8-FD10712F0759Q28068014-1FB17FE3-3823-4612-AA48-173FEA206576Q28535157-C627D2D8-493D-4FE7-8B12-25D571C11400Q33581531-9A3B4FC4-2D4B-4998-B35F-B9AC77418E2BQ33746585-508CC069-0630-4905-97D9-0FD38E321844Q34066977-3568E4FB-7C1B-42A1-9DCD-3FBAC5356117Q34276618-0EC64FE6-B529-4B31-B0FE-CDDA9A162ACFQ34612244-0FD2783D-66DF-4CBB-88A0-239142191F59Q34631971-B39E9F3E-FF50-4FBE-814D-9349D79E1A83Q35079707-803B017E-35B5-4915-B605-1EEB1C9E6679Q35183649-9EF8F542-FC5A-447F-9570-D5AD14C4F0D1Q35194778-B63AB2F4-24D2-4B09-9619-033E394A9A3EQ35683911-B1745E97-4F48-41E1-8123-FB3D21F739FAQ35826894-C9D71AF7-9356-479D-A9BB-8E6E703F5B66Q35879055-11153D53-4050-4053-AB6D-15C5EDF81AF1Q35915932-22271925-FA3D-431D-8EEA-9514B8E5AEA1Q36040772-E8D03ED6-CB4F-41C5-A963-297FDC561C31Q36052505-4F7EEAEB-E379-44F5-A6C7-297E68957B09Q36123304-7E0293AC-5DEC-4137-B960-F5CEB4733E40Q36188328-B2D10618-4248-494F-8CB3-097F8C74CBA3Q36233941-E6AD9626-7DA0-4E73-B81D-2A8A7D5449FEQ36288839-83ACD06D-09D1-42AD-A65B-A5CB2CA55B78Q36303810-3F701432-B9A5-4B5E-A834-17DAAE891E9AQ36349758-4CB3E4B6-106B-4806-B64D-D6654E386930Q36544962-C7F5890E-E237-4604-8545-5F18F5875044Q36544966-A4B69B42-4678-498A-A71E-09C1F6380762Q36649880-3D2AF684-F8C5-4101-9411-6865780942D8Q36752063-C62B1A09-541B-4CA2-8B69-0712D657737FQ36951933-7B38994E-6825-4D30-96EE-49996DFA3E09Q36985076-219BA610-08AC-43CB-A0C7-D7515DC01E6CQ36986507-63361630-BF23-4D75-9C4A-CB297AC71B7EQ37074085-C891CEAB-E058-404F-B16D-111B7D610A20Q37114391-1FE13A10-6F99-43CB-8363-7A0434CAA4B4Q37167517-EE131E7B-BA67-45EB-A676-D0BB55F24DE4Q37214523-1E28E01A-2175-4C95-B57D-B783EB99DFB2Q37329141-1AB80F87-7D4E-4818-B566-88F4C3DAB9DEQ37331801-2F3D254F-C5FD-4324-A11C-9D5100D394AFQ37331821-D2BDC38C-D0C0-42E7-B9B4-0D30A08FBA45Q37367666-4F80088E-1D78-45EA-9961-5B251BAAB0C8
P2860
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
description
2004 nĆ® lÅ«n-bĆ»n
@nan
2004幓ć®č«ę
@ja
2004幓č«ę
@yue
2004幓č«ę
@zh-hant
2004幓č«ę
@zh-hk
2004幓č«ę
@zh-mo
2004幓č«ę
@zh-tw
2004幓č®ŗę
@wuu
2004幓č®ŗę
@zh
2004幓č®ŗę
@zh-cn
name
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
@en
type
label
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
@en
prefLabel
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
@en
P2093
P1476
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
@en
P2093
Amy S Windass
Bruce K Birmingham
Colin D A Brown
Dennis W Schneck
Julie A Zalikowski
Kenneth C Lasseter
Patrick D Mitchell
Paul D Martin
P304
P356
10.1016/J.CLPT.2003.12.014
P407
P577
2004-05-01T00:00:00Z